Anti-IL5 Monoclonal Antibodies Reduce Asthma Exacerbations and Corticosteroids Dose in Three Eosinophilic Granulomatosis with Polyangiitis Case Reports.
asthma
case report
corticosteroids
eosinophilic granulomatosis with polyangiitis
monoclonal antibodies
Journal
Mediterranean journal of rheumatology
ISSN: 2529-198X
Titre abrégé: Mediterr J Rheumatol
Pays: Greece
ID NLM: 101730166
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
18
11
2022
revised:
17
01
2023
accepted:
19
01
2023
medline:
1
9
2023
pubmed:
1
9
2023
entrez:
1
9
2023
Statut:
epublish
Résumé
Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare multisystem necrotizing small and medium-sized vessel vasculitis with eosinophilic adult-onset asthma as part of its spectrum. Therapeutic choices include corticosteroids, immunosuppressive agents, and novel immunomodulators. Mepolizumab and benralizumab are monoclonal antibodies targeting Interleukin-5 (IL-5), which plays a leading role in every stage of production and maturation of eosinophils and are recently undergoing evaluation and administered in steroid-dependent, relapsing and/or refractory EGPA. Herein we describe the cases of three patients with a prior EGPA diagnosis, experiencing frequent asthmatic exacerbations despite oral and inhaled corticosteroid treatment (two patients) and adverse effects of corticosteroids (one patient). Two patients are under treatment with mepolizumab and one patient with benralizumab as an add-on supplemental regimen. In our case series anti-IL5 monoclonal antibodies proved efficient asthma-controlling and corticosteroid-sparing agents.
Identifiants
pubmed: 37654647
doi: 10.31138/mjr.34.2.238
pii: MJR-34-2-238
pmc: PMC10466358
doi:
Types de publication
Journal Article
Langues
eng
Pagination
238-244Informations de copyright
© 2023 The Mediterranean Journal of Rheumatology (MJR).
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Allergy Clin Immunol Pract. 2020 Oct;8(9):3225-3227.e2
pubmed: 32505716
Allergy Asthma Clin Immunol. 2022 Feb 19;18(1):14
pubmed: 35183225
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1186-1193.e1
pubmed: 33065367
Mod Rheumatol. 2022 Feb 28;32(2):387-395
pubmed: 34910206
Arthritis Rheumatol. 2021 Aug;73(8):1366-1383
pubmed: 34235894
Ann Rheum Dis. 2022 Mar;81(3):309-314
pubmed: 35110334
Arthritis Rheum. 2013 Jan;65(1):270-81
pubmed: 23044708
Lancet. 2012 Aug 18;380(9842):651-9
pubmed: 22901886
Clin Rheumatol. 2021 Dec;40(12):4829-4836
pubmed: 34159493
Intern Med. 2023 May 15;62(10):1553-1556
pubmed: 36171130
N Engl J Med. 2017 May 18;376(20):1921-1932
pubmed: 28514601
Arthritis Rheumatol. 2022 Feb;74(2):295-306
pubmed: 34347947
Curr Rheumatol Rep. 2021 Apr 28;23(6):38
pubmed: 33909172
Ann N Y Acad Sci. 2005 Jun;1051:121-31
pubmed: 16126951
Medicine (Baltimore). 1999 Jan;78(1):26-37
pubmed: 9990352
Rheumatology (Oxford). 2020 May 1;59(Suppl 3):iii84-iii94
pubmed: 32348510
Drugs. 2018 Jun;78(8):809-821
pubmed: 29766394